Compare Newmont Corporation (NEM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Repligen Corporation Common Stock — how do they compare? Newmont Corporation trades at $113 (market cap $117.55B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Newmont Corporation is far larger — about 10.4× Repligen Corporation Common Stock's market cap, and Newmont Corporation pays a 0.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Repligen Corporation Common Stock for 0 Days on average.
| NEM | RGEN | |
|---|---|---|
Market Cap | $117.55B | $11.31B |
Volume | 6,644,300 | 1,216,919 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $194.57 |
52-Week Low | $78.63 | $102.87 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.14B | $11.20B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $115.59, down 1.33% on the day, as the gold mining giant demonstrates strong fundamental performance with record revenue of $22.67 billion in 2025 and net income of $7.09 billion. The stock shows a bullish technical trend with support at $115 and resistance at $118, while maintaining attractive valuation metrics including a P/E of 14.58 and ROE of 25.53%. Recent news highlights the company's record $5.3 billion free cash flow and focus on per-share growth through operational improvements.
Newmont presents a compelling investment case with strong analyst support (76% buy ratings) and a $136.83 consensus price target representing 18% upside. The company's transformation from losses in 2022-2023 to robust profitability, coupled with disciplined capital allocation and gold price tailwinds, supports continued growth. Key risks include gold price volatility, operational execution challenges, and broader market conditions that could pressure mining stocks despite strong fundamentals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
